IG Farben Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Frankfurt Germany (1925)
Status: Defunct (1951)

Organization Overview

First Clinical Trial
None
First Marketed Drug
1981
ibuprofen (motrin)
First NDA Approval
None
Last Known Activity
1981

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

ibuprofen (motrin) (1981)

Drugs in Phase 4 Trials (2)

Key: IG Farben (0) Acquired (2)

etanercept (enbrel) (1 trial)

icosapent ethyl (vascepa) (16 trials)

Drugs in Phase 3 Trials (3)

Key: IG Farben (0) Acquired (3)

corn (2 trials)

omega-3 fatty acids (Omacor) (3 trials)

vitamin e (1 trial)

Drugs in Phase 2 Trials (4)

Key: IG Farben (0) Acquired (4)

icosabutate (5 trials)

olive (6 trials)

prevastein hc (1 trial)

vitamin a (1 trial)

Drugs in Phase 1 Trials (1)

Key: IG Farben (0) Acquired (1)

ethinyl estradiol (Estinyl) (1 trial)

Drugs in Other Trials (11)

Key: IG Farben (0) Acquired (11)

carotenoid (1 trial)

conjugated linoleic acid (3 trials)

cow milk (1 trial)

docosahexaenoic acid (3 trials)

eicosapentanoic acid (3 trials)

fatty acid (1 trial)

fish oil (Omegavan) (1 trial)

gamma-aminobutyric acid (1 trial)

safflower oil (1 trial)

vitamin d3 (1 trial)

xanthophyll (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 39
  • # of Trial APIs: 21